Medvarsity Logo
Thumbnail for CAR-T Cell Therapy: Current Advances, Challenges, and the Road Ahead  -The BCMA Frontier

CASE DISCUSSION

CAR-T Cell Therapy: Current Advances, Challenges, and the Road Ahead -The BCMA Frontier

India flagPresented India by Dr. Shibichakravarthy Kannan

Views

4

Case Description

This webinar will explore the evolving landscape of CAR-T cell therapy, with a focus on BCMA-targeted approaches in hematological malignancies. The session will discuss current advances in BCMA CAR-T therapies, patient selection, clinical outcomes, and key challenges such as treatment resistance...

Case Summary

  • Multiple myeloma is a clonal plasma cell malignancy characterized by osteolytic bone destruction, hypercalcemia, renal impairment, anemia, and profound humoral immune dysfunction. Within the specialized bone marrow microenvironment, malignant plasma cell survival and proliferation are driven by signaling through B-cell maturation antigen, or BCMA, and transmembrane activator and CAML interactor, known as TACI, via the ligands APRIL and BAFF. While BCMA has emerged as a premier target for chimeric antigen receptor T-cell therapy, including agents such as idecabtagene vicleucel and ciltacabtagene autoleucel, long-term efficacy is frequently hindered by disease relapse within nine to twelve months. Two predominant mechanisms underlie this therapeutic failure: enzymatic cleavage of cell-surface BCMA by membrane-bound gamma-secretase, which generates soluble decoy receptors that neutralize circulating CAR-T cells, and biallelic genetic deletion leading to complete antigen loss.

Speaker Profile

Dr. Shibichakravarthy Kannan

Dr. Shibichakravarthy Kannan

Precision Oncology, Founder & CEO in Oncophenomics Inc., Hyderabad

Disclosures

Assimilate by Medvarsity requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.